Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06628141
Recruiting Not applicable

Enhancing Quality of Life in Cancer Patients Through Tailored Nutrition Support: a Comprehensive Approach

NCT06628141 · tracked via the Priya Life Science Spain tracker
Sponsor
UOMi Cancer Center
Phase
Not applicable
Started
2023-11-14
Last updated
2024-10-04

Condition(s) studied

Cancer

Investigational drug(s) / intervention(s)

Nutritional support tool

Nutritional support tool: Nutritional support tool

Study summary

The study aims to investigate the impact of a dedicated nutritional assistance tool on patients with cancer and to measure its effects on several proposed indicators.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients affected by cancer, who decided to participate to the study, signed the informed consent and whose life expectancy is higher than 1 (one) year. Exclusion Criteria: * Patients with an eating disorder of psychiatric or psychological origin, diagnosed before cancer treatment. * Any other exclusion criteria as determined by the oncologist based on the patient's ability to successfully complete the program.

Primary outcome measure(s)

  • Outcome Measure: Dietary Adherence — 1 year
    Dietary adherence will be measured by comparing the planned recipes provided to participants with the meals they report consuming each week. Participants receive 21 recipe suggestions (7 breakfasts, 7 lunches, 7 dinners) via a mobile app. The following tools and methods will assess adherence: Mobile Application Tracking: The app tracks participants' views of recipes and ingredient purchases via the integrated shopping list. Weekly Questionnaire: A self-reported questionnaire asks if participants: Followed the recipes using ingredients purchased via the app. Prepared recipes with their own ingredients. Ate meals not included in the plan. Adherence Calculation: Adherence is calculated as the ratio of recipes followed (via app or self-preparation) to the total number of recommended recipes (21 per week), expressed as a percentage.

Trial sites (1)

FacilityCityRegionStatus
UOMI Cancer Center Clínica Mi Tres Torres Barcelona Barcelona Recruiting

Other trials for the same condition

Study of IMC-P115C in Advanced PRAME-Positive Cancers Recruiting
Physiotherapy in Pediatric Oncology Starting soon
Efficacy of a Combined ACT+ App Intervention to Improve Psychological Flexibility and Associated Symptoms in Cancer Patients Active, not recruiting
Met Non Small Cell Cancer Registry (MOMENT) Recruiting
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06628141 on ClinicalTrials.gov ↗ ← All trials in Spain